Every 8-K that Kalaris Therapeutics, Inc. (KLRS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow KLRS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KLRS filings page.
Kalaris Therapeutics, Inc. reported second quarter 2026 results and provided updates on its lead retinal therapy candidate TH103. Patient dosing is ongoing in a Phase 1b/2 trial in neovascular age-related macular degeneration, with preliminary data anticipated in the first half of 2027, and potential Phase 3 trials remain on track for initiation by year-end 2027.
As of June 30, 2026, Kalaris held $93.5 million in cash, cash equivalents and marketable securities, which it expects will fund operations into the fourth quarter of 2027 and through key clinical milestones. For the quarter ended June 30, 2026, research and development expenses were $9.0 million and general and administrative expenses were $3.4 million. Net loss for the quarter was $11.5 million, or $0.48 per share, compared with a net loss of $11.4 million, or $0.61 per share, for the same period in 2025.
Kalaris Therapeutics, Inc. appointed Liisa Bayko as Chief Financial Officer, Treasurer and principal financial officer effective July 20, 2026. Her Employment Agreement provides a base salary of $475,000, eligibility for an annual bonus of up to 40.0% of base salary, and standard non‑competition, non‑solicitation and confidentiality covenants.
Bayko received an incentive stock option to purchase 220,000 shares of common stock, with an exercise price set at the Nasdaq closing price on the effective date. The option vests 25% on the first anniversary of her start date and monthly over 36 months thereafter, subject to continued service. If terminated without cause or for good reason outside a change in control window, she may receive nine months of base salary and COBRA premium support; this increases to 12 months of salary, a bonus equal to 100% of target, extended COBRA premium support and full time‑based equity vesting if such a termination occurs in proximity to a change in control.
Brett Hagen resigned as Senior Vice President, Finance and Chief Accounting Officer effective July 27, 2026. The Board designated Amy Vandekop, Corporate Controller, as interim principal accounting officer effective the same date, with no changes to her existing compensation arrangements. Both Bayko and Vandekop entered into indemnification agreements covering certain legal expenses arising from their service as officers.
Kalaris Therapeutics reported positive additional data from its expanded Phase 1a single ascending dose trial of TH103 in treatment-naïve neovascular age-related macular degeneration. The dataset now covers 17 treatment-naïve and 3 treatment-experienced patients, all followed for six months, and continues to show robust structural and functional vision improvements.
TH103 demonstrated pharmacokinetics suggesting extended intraocular retention, with 27- to 53-fold lower plasma Cmax than leading anti-VEGF agents on a molar basis. After a single injection, 41% of treatment-naïve patients were retreated at four months or later and 29% needed no additional anti-VEGF therapy over six months; treatment-experienced patients saw an average two‑month extension in retreatment intervals. No intraocular inflammation occurred in six patients at the 2.5 mg dose produced with an improved process, while one prior 5 mg patient had transient inflammation that resolved. Kalaris is enrolling a Phase 1b/2 multiple-ascending dose study using a four-dose loading regimen in treatment-naïve patients and remains on track to share initial data in the first half of 2027; investor materials also indicate cash runway into Q4 2027.
Kalaris Therapeutics reported a board change and related director compensation. Morana Jovan-Embiricos, Ph.D., resigned from the board and the Audit Committee, and stated her resignation was not due to any disagreement with the company’s operations, policies or practices.
The board elected Laurie Keating as a Class I director, effective August 1, 2026, with a term running to the 2027 annual meeting. She will also join the Audit Committee. As a non-employee director, she will receive an option for 18,000 shares vesting over three years, annual cash fees for board and committee service, ongoing equity grants under the director compensation policy and standard indemnification protection.
Kalaris Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders on June 3, 2026. Stockholders elected directors Napoleone Ferrara, M.D., David Hallal, and Leone Patterson, with each receiving more than 15.6 million votes in favor and roughly 0.5–0.7 million votes withheld.
Stockholders cast an advisory vote on executive compensation and a separate advisory vote on how often to hold future executive compensation votes. A large majority, with 16,336,117 votes, supported holding this advisory vote every year. After reviewing these results, the Board of Directors plans to conduct future advisory votes on named executive officer pay annually. Another proposal received 19,771,260 votes for, 1,583 against, and 601 abstentions.
Kalaris Therapeutics reported first‑quarter 2026 results and highlighted progress in its retinal disease program TH103. As of March 31, 2026, the company held $104.9 million in cash, cash equivalents and marketable securities and expects this to fund operations into the fourth quarter of 2027 and through key clinical milestones.
Research and development expenses rose to $7.6 million from $6.0 million a year earlier as additional clinical sites were opened and patients enrolled. General and administrative expenses were stable at $4.3 million. Net loss was $10.9 million, compared with $10.2 million in the prior‑year quarter, with no revenue reported.
The company has begun patient screening in its Phase 1b/2 trial of TH103 for neovascular age‑related macular degeneration and has manufactured new clinical material for upcoming dosing. It anticipates preliminary Phase 1b/2 data in the first half of 2027 and continues to plan Phase 3 trials targeted for initiation by year‑end 2027.
Kalaris Therapeutics, Inc. announced that Chief Financial Officer Matthew Gall will resign effective April 14, 2026. In connection with his departure, Brett Hagen, the current Chief Accounting Officer and principal accounting officer, will also serve as the company’s principal financial officer from the same date.
The filing outlines Mr. Hagen’s prior senior finance roles at several biopharmaceutical companies and his academic background in accounting and finance. It also notes that he has no family relationships with directors or officers, no related-party transactions requiring disclosure, and that his compensation arrangements remain unchanged.
Kalaris Therapeutics reported a narrower full-year 2025 net loss of $43.4 million, improved from $69.2 million in 2024, as it advanced its lead retinal drug candidate TH103.
Cash, cash equivalents and marketable securities rose to $118.0 million as of December 31, 2025, from $1.6 million a year earlier, driven by its March 2025 merger with AlloVir and an oversubscribed $50.0 million private placement in December. The company expects this cash to fund operations into the fourth quarter of 2027.
Research and development expenses fell to $30.8 million from $45.0 million, largely reflecting a prior-year royalty obligation, while general and administrative costs increased to $15.4 million from $6.7 million as Kalaris scaled public-company infrastructure. Shares outstanding were 22,902,418 as of December 31, 2025.
Clinically, Kalaris reported positive initial Phase 1a single ascending dose data in neovascular age-related macular degeneration, noting TH103 was generally well tolerated with no dose-limiting toxicities or treatment-related serious adverse events. An ongoing Phase 1b/2 multiple ascending dose trial began enrolling in 2025, with preliminary data expected in the first half of 2027, and the company intends to start Phase 3 trials by year-end 2027.
Kalaris Therapeutics, Inc. furnished an updated corporate presentation outlining development plans and early data for its lead retinal therapy candidate, TH103. The company highlights TH103 as an engineered anti-VEGF fusion protein designed for extended intraocular retention and enhanced VEGF inhibition in neovascular retinal diseases such as nAMD.
Initial Phase 1a single-ascending dose data showed rapid, robust improvements in visual acuity and retinal fluid measures at one month, with TH103 generally well tolerated and no dose-limiting toxicities reported. An ongoing Phase 1b/2 multi-dose trial in nAMD is underway, with preliminary data expected in the first half of 2027 and potential Phase 3 initiation planned by year-end 2027, subject to results.
The presentation also notes a $50 million oversubscribed private placement completed in December 2025 and states that the company’s cash runway is expected to fund operations into the fourth quarter of 2027. Kalaris emphasizes continued manufacturing process refinements aimed at reducing host cell protein levels and outlines intellectual property protection for TH103 compositions and methods of use, with U.S. exclusivity expected into the early 2040s.
Kalaris Therapeutics, Inc. entered into a private placement with institutional accredited investors to raise approximately $50.0 million in gross proceeds. The company agreed to sell 4,200,000 shares of common stock at $10.00 per share and issue pre-funded warrants to purchase 800,000 shares of common stock at $9.9999 per warrant, each warrant carrying an exercise price of $0.0001 per share and being exercisable immediately until fully exercised.
The private placement is expected to close on or about December 19, 2025, subject to customary conditions, with Morgan Stanley & Co. LLC and Leerink Partners LLC as lead placement agents. Kalaris expects that its cash, cash equivalents and short-term investments, together with anticipated net proceeds from this financing, will be sufficient to fund operating expenses and capital expenditures into the third quarter of 2027. The company also agreed to register the resale of the new shares and warrant shares under a future registration rights agreement.
Kalaris Therapeutics reported initial data from its Phase 1a single ascending dose trial of TH103 in treatment-naïve patients with neovascular age-related macular degeneration. The study used a single intravitreal injection at three dose levels (0.5 mg, 1.5 mg, 2.5 mg) in 13 patients who completed six months of follow-up and showed robust improvements in vision and retinal anatomy that are consistent with TH103’s molecular design and preclinical profile.
TH103 was generally well tolerated. Two cases of transient, mild to moderate intraocular inflammation occurred at the 2.5 mg dose and were linked to host cell protein levels in the drug product; after adding extra purification steps, six more patients received the 2.5 mg dose with the new material and no additional inflammation events were seen at one week or more of follow-up. The company is using this updated drug product in ongoing and planned studies and is enrolling a Phase 1b/2 multi-ascending dose, dose-finding trial of four monthly injections, with preliminary data expected in the second half of 2026.
Kalaris Therapeutics (KLRS) furnished an 8-K announcing it issued a press release with financial results for the quarter ended September 30, 2025. The press release is provided as Exhibit 99.1 and incorporated by reference as stated.
The company notes the information, including Exhibit 99.1, is being furnished and not filed under the Exchange Act. Kalaris Therapeutics’ common stock trades on The Nasdaq Global Market under the symbol KLRS.
Kalaris Therapeutics (KLRS) appointed Matthew Gall as Chief Financial Officer and Treasurer, effective November 3, 2025. He will also serve as principal financial officer. The board approved an Employment Agreement with an annual base salary of $485,000 and an annual incentive bonus opportunity of up to 40% of base salary.
As part of his compensation, Mr. Gall received an option to purchase 235,000 shares of common stock at the Nasdaq closing price on the effective date, vesting 25% on the first anniversary and monthly over 36 months thereafter, subject to continued service. Severance terms include nine months of base salary and COBRA premiums if terminated without cause or for good reason outside a change in control window, and, in a change in control window, 12 months of base salary, a lump-sum 100% Target Bonus, up to 12 months COBRA premiums, and full acceleration of time‑based equity.
Brett Hagan ceased serving as principal financial officer on the effective date and continues as principal accounting officer.
Kalaris Therapeutics held its 2025 annual meeting on August 12, 2025. Stockholders elected Srinivas Akkaraju, M.D., Ph.D. and Andrew Oxtoby as Class II directors, each to serve three-year terms through the 2028 annual meeting. Vote counts reported were 14,626,646 For, 144,695 Withheld and 1,328,348 Broker Non-Votes for Dr. Akkaraju and 14,668,424 For, 102,917 Withheld and 1,328,348 Broker Non-Votes for Mr. Oxtoby.
Shareholders also ratified Deloitte & Touche LLP as the company’s independent registered public accounting firm for the 2025 fiscal year, with 16,090,928 For, 6,975 Against and 1,786 Abstain. These results reflect routine corporate governance actions reported to the market.
Kalaris Therapeutics, Inc. furnished a press release announcing its financial results for the quarter ended June 30, 2025. The press release is provided as Exhibit 99.1 to this Form 8-K and is incorporated by reference.
This Current Report itself does not include any financial figures or operating metrics; it states that the information in the press release is being furnished and shall not be deemed "filed" under the Exchange Act. The filing was submitted on behalf of the company and is signed by Chief Executive Officer Andrew Oxtoby. Readers must consult Exhibit 99.1 for the detailed results.
Kalaris Therapeutics, Inc. (Nasdaq: KLRS) has filed a Form 8-K to announce scheduling details for its 2025 Annual Meeting of Stockholders.
The Board of Directors set August 12, 2025 as the meeting date. Because this date is more than 30 days later than the 2024 meeting anniversary, the company has adjusted deadlines for shareholder engagement:
- Rule 14a-8 proposals: Must be received by the Corporate Secretary no later than June 30, 2025 to be considered for inclusion in the proxy statement.
- Director nominations or other business under the company’s By-laws: Notice must also be delivered by June 30, 2025, in line with Section 2(a)(2) of the By-laws, because the meeting date is delayed by more than 60 days from the prior-year anniversary.
The filing contains no financial results, strategic transactions, or operational updates. Further details—such as the exact time, physical or virtual location, and the matters up for vote—will be provided in the forthcoming proxy statement.
The disclosure is routine, ensuring regulatory compliance and giving shareholders clear deadlines to submit proposals or nominations.